Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston. It was launched in 2024 and develops medicines for neuropsychiatric disorders such as depression, anxiety and related conditions.

The company's work is built on its Glyph platform. This technology attaches drugs to dietary lipid pathways so that oral medicines are absorbed through the lymphatic system and avoid first-pass metabolism in the liver. The aim is to make effective drugs usable as oral treatments when liver metabolism or liver toxicity would otherwise limit them, and to improve their tolerability.

Seaport's pipeline includes several product candidates that use the Glyph technology, applied to compounds with established mechanisms of action in psychiatry and neurology.